|
|
News Breaks | | | | November 1, 2012 | | 07:25 EDT |  | OMER | Omeros announces enrollment in Phase 1 clinical trial evaluating OMS824
Omeros announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10, or PDE10, program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease. This Phase 1 dose-ranging study is evaluating the drug's safety, tolerability and pharmacokinetics in healthy subjects, and Omeros expects clinical data before year end. | |
|
News For OMER From The Last 14 Days Check below for free stories on OMER the last two weeks. |
|
|
| May 10, 2013 | | 07:00 EDT |  | OMER | Omeros reports Q1 EPS (40c), consensus (40c)
 Subscribe for More Information | | | May 9, 2013 | | 18:34 EDT |  | OMER | Omeros announces $16.2M registered direct offering of common stock
Subscribe for More Information | |
|
|
|
|
|
|
